Cargando…

A Review of the Multi-Systemic Complications of a Ketogenic Diet in Children and Infants with Epilepsy

Ketogenic diets (KDs) are highly effective in the treatment of epilepsy. However, numerous complications have been reported. During the initiation phase of the diet, common side effects include vomiting, hypoglycemia, metabolic acidosis and refusal of the diet. While on the diet, the side effects in...

Descripción completa

Detalles Bibliográficos
Autores principales: Newmaster, Kyra, Zhu, Zahra, Bolt, Elizabeth, Chang, Ryan J., Day, Christopher, Mhanna, Asmaa, Paudel, Sita, Farooq, Osman, Swaminathan, Arun, Acharya, Prakrati, Cheungpasitporn, Wisit, Gupta, Siddharth, Samanta, Debopam, Mahfooz, Naeem, Mainali, Gayatra, Carney, Paul R., Naik, Sunil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498174/
https://www.ncbi.nlm.nih.gov/pubmed/36138681
http://dx.doi.org/10.3390/children9091372
Descripción
Sumario:Ketogenic diets (KDs) are highly effective in the treatment of epilepsy. However, numerous complications have been reported. During the initiation phase of the diet, common side effects include vomiting, hypoglycemia, metabolic acidosis and refusal of the diet. While on the diet, the side effects involve the following systems: gastrointestinal, hepatic, cardiovascular, renal, dermatological, hematologic and bone. Many of the common side effects can be tackled easily with careful monitoring including blood counts, liver enzymes, renal function tests, urinalysis, vitamin levels, mineral levels, lipid profiles, and serum carnitine levels. Some rare and serious side effects reported in the literature include pancreatitis, protein-losing enteropathy, prolonged QT interval, cardiomyopathy and changes in the basal ganglia. These serious complications may need more advanced work-up and immediate cessation of the diet. With appropriate monitoring and close follow-up to minimize adverse effects, KDs can be effective for patients with intractable epilepsy.